Brand-name drug
Truvada price, strengths & recalls
Brand of emtricitabine / tenofovir disoproxil (generic)
Pharmacies pay $1,787.78 for 30 tablets of Truvada 200 mg / 300 mg tablet this week. The generic, emtricitabine / tenofovir disoproxil, costs pharmacies from $15.79. It has 1 recall on record, none ongoing. Its official label last changed on July 25, 2025.
Brand- Fair cash price
- $2,066.45
- Strengths
- 1
- Makers
- 1
- Updated
- Nov 11
Truvada price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 200 mg / 300 mg tablet Brand | $59.59 | $1,787.78 / 30 tablets |
Truvada vs generic emtricitabine / tenofovir disoproxil
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 200 mg / 300 mg tablet | $1,787.78 | $15.79 | 113.2x |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Truvada
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use TRUVADA safely and effectively. See full prescribing information for TRUVADA. TRUVADA® (emtricitabine and tenofovir disoproxil fumarate) tablets, for oral use Initial U.S. Approval: 2004
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed [see Warnings and Precautions (5.2)].
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION
See full prescribing information for complete boxed warning.
Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely in these individuals who discontinue TRUVADA. If appropriate anti-hepatitis B therapy may be warranted. (5.1)
TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with the use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate TRUVADA for HIV-1 PrEP if signs or symptoms of acute HIV infection are present unless negative infection status is confirmed. (5.2)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021752 · Gilead
- First approved
- August 2, 2004 (22 years ago)
- Latest approved change
- April 29, 2024
- Approved label
- PDF, Apr 30, 2024
- Generic makers
- 11 approved generic applications on the market
Truvada questions
How much does truvada cost without insurance?
Pharmacies pay about $1,787.78 for 30 tablets of truvada 200 mg / 300 mg tablet ($59.59 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $2,066.45. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Truvada?
Yes: emtricitabine / tenofovir disoproxil. Pharmacies pay from $15.79 for it. Compare emtricitabine / tenofovir disoproxil prices.
Is truvada in shortage?
No shortage is reported for truvada right now. We check the national shortage list every day.
Has truvada been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the truvada label last change?
The official label was last updated on July 25, 2025 (version 32). See what changed.
Talk about truvada
No comments yet. Questions, tips, what worked for you - start the conversation.